KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has attracted significant investment activity from Venrock Healthcare Capital ...
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term ...
What:              Cahoots Theatre, in collaboration with the Alzheimer Society of Toronto, presents Love and the Trick of Time, an innovative and deeply moving multidisciplinary production. Directed ...
Bio-Techne Corporation today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of ...
Citizens Jmp upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) to a strong-buy rating in a report ...
Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a ...
The investment bank believes that deucrictibant will outsell KalVista Pharmaceuticals,(KALV) sebetralstat if both treatments for HAE are approved. Meanwhile, based on the data from Pharvaris ...
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) passed above its 50-day moving average during trading on Wednesday .The stock has a 50-day moving average of $8.87 and ...
Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Market Outperform recommendation. As of January 28, 2025, the average ...